Pay in 4 interest-free payments of $7.20 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Latvala, S., Jacobsen, B., Otteneder, M
9 These are encouraging results, and they confirm that Mounjaro has genuine cardiovascular benefits beyond supporting weight loss
Sukul, Anemia and iron deficiency among chronic kidney disease Stages 35ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated
Most recent policy updates reviewed: December 2025 Government Programs: What's Changing Medicare Coverage Expanding Medicare coverage for Wegovy is expanding for eligible beneficiaries: January 2027: Under the CMS BALANCE Model, Medicare Part D will cover obesity medications including Wegovy CMS program: Eligible Medicare beneficiaries will pay $50/month for GLP-1 medications under the BALANCE demonstration Current: Wegovy can be covered for CV risk reduction indication (not weight loss) Medicaid Coverage: State-by-State About a dozen state Medicaid programs currently cover GLP-1s for obesity, with policies evolving
US$ 27.41
US$ 23.21
US$ 23.16
US$ 20.51
US$ 22.09
